



IBA Introduces NEW COMPASS *QuickCheck*™ Functionality for Safer and More Efficient Cancer Treatment

- **COMPASS provides more efficiency with the new COMPASS *QuickCheck*.**
- **Accidental linac dose delivery deviations detected easily with Pass/Fail indication.**

Schwarzenbruck, Germany, May 22, 2014 – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of proton therapy solutions and radiation therapy dosimetry for the treatment of cancer, announces the release of COMPASS 3.1 with the new COMPASS *QuickCheck* feature. COMPASS *QuickCheck* allows for fully automated gamma analysis in just one look, and automatic Pass/Fail is instantly indicated based on customers' protocol thereby replacing human subjectivity. COMPASS now offers more efficiency and full workflow flexibility, allowing physicists and dosimetrists to choose the most efficient QA for any clinical need, whether measurement or calculation based.

“COMPASS is used to verify every IMRT and VMAT plan fast with 3Dcomputations. A huge advantage compared to other patient QA systems is the possibility of optionally conducting dose reconstructions based on MatriXX measurement,” say Mark P. Arends and Alle H. Ausma, medical physicists at Radiotherapy Institute Friesland, Leeuwarden, Netherlands. “Accidental linac dose delivery deviations from the treatment plan can be detected. The user can specify his own criteria for selecting the desired detection level. With the implemented 2D QuickCheck, module deviations between expected and measured chamber response result automatically in a pass or fail indication.”

With its powerful Collapsed Cone Algorithm for independent dose calculations, COMPASS allows TPS-class dose calculations on real patient CT, real patient CT-based DVH, and global and local 3D Gamma. Additionally, independent beam modelling of individual linacs enables flexibility in precisely modelling as many machines as needed for highly accurate plan verifications. Physicists can measure and compare real linac delivery vs. TPS-planned delivery as well as analyze the effect of segment errors on the total treatment accuracy.

*“We are pleased to release the newest version of COMPASS with the new COMPASS *QuickCheck*, which offers significant efficiency that we feel is the most robust patient plan verification system available today. We are confident that this newest version of COMPASS is a huge step forward in the field of plan verification and provides safer radiation therapy”, remarked Ralf Schira, Vice President of Marketing for IBA Dosimetry.*

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.



Headquartered in Belgium and employing more than 1,000 people worldwide, IBA has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Media Contact:

Ralf Schira
Vice President Marketing
IBA Dosimetry GmbH
Bahnhofstrasse 5
90592 Schwarzenbruck, Germany
Tel: +49 089 45109765
Ralf.schira@iba-group.com

Suzanne Shankle
Marketing Specialist
IBA Dosimetry Americas
3150 Stage Post Drive, Suite 110
Bartlett, TN 38133
Tel: (901) 386-2242
Suzanne.shankle@iba-group.com

<http://www.iba-dosimetry.com>

Press release | **May 22, 2014**

###